

## Four simple steps to submit your referral.

Do not contact patient, benefits check only

### 1 Patient Information

New patient    Current patient

Patient's first name \_\_\_\_\_ Last name \_\_\_\_\_ Middle initial \_\_\_\_\_

Sex at birth: Male Female Preferred pronouns \_\_\_\_\_ Last 4 digits of SSN \_\_\_\_\_ Date of birth \_\_\_\_\_

Street address \_\_\_\_\_ Apt # \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Parent/guardian (if applicable) \_\_\_\_\_ Phone \_\_\_\_\_

Patient's primary language: English Other If other, please specify \_\_\_\_\_



Please attach copies of front and back of patient's insurance cards.

Insurance Company \_\_\_\_\_ Phone \_\_\_\_\_

Identification # \_\_\_\_\_ Policy/group # \_\_\_\_\_

Prescription card: Yes No If yes, carrier \_\_\_\_\_ Policy #: \_\_\_\_\_ Group # \_\_\_\_\_

### 2 Prescriber Information

Date \_\_\_\_\_ Time \_\_\_\_\_ Date medication needed \_\_\_\_\_

Office/clinic/institution name \_\_\_\_\_

**Prescriber info:** Prescriber's first name \_\_\_\_\_ Last name \_\_\_\_\_

Prescriber's title \_\_\_\_\_ If NP or PA, under direction of Dr. \_\_\_\_\_

Office phone \_\_\_\_\_ Fax \_\_\_\_\_ NPI # \_\_\_\_\_ License # \_\_\_\_\_

Office contact and title \_\_\_\_\_ Office contact email \_\_\_\_\_

Office street address \_\_\_\_\_ Suite # \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Infusion location: Patient's home Prescriber's office Infusion site If infusion site, complete information below dotted line:  
-----

**Infusion info:** Infusion site name \_\_\_\_\_ Clinic/hospital affiliation \_\_\_\_\_

Site street address \_\_\_\_\_ Suite # \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Infusion site contact \_\_\_\_\_ Phone \_\_\_\_\_ Fax \_\_\_\_\_ Email \_\_\_\_\_

### 3 Clinical Information

CHECK ONE

**ICD-10 immunology:** D80.0 Congenital Hypogam D83.9 CVID (unspecified) D81.9 SCID (unspecified)

**ICD-10 neurology:** G61.81 CIDP G61.82 MMN G35 MS (rel remit) G61.0 GBS G70.01 MG

**ICD-10 rheumatology:** M33.20 Polymyositis M33.90 Dermatomyositis

**Other** \_\_\_\_\_

Other drugs used to treat the disease \_\_\_\_\_

Weight \_\_\_\_\_ kg/lbs Height \_\_\_\_\_ cm/in Date recorded \_\_\_\_\_

NKDA Known drug allergies \_\_\_\_\_

Concurrent meds \_\_\_\_\_

Patient's first name \_\_\_\_\_ Last name \_\_\_\_\_ Middle initial \_\_\_\_\_ Date of birth \_\_\_\_\_

Prescriber's first name \_\_\_\_\_ Last name \_\_\_\_\_ Phone \_\_\_\_\_

## 4 Prescribing Information

Medication	Strength/Formulation	Directions															
<b>Select one or multiple preferred SCIG brand-name products you have authorized and are clinically appropriate for your specific patient. Single drug selection required for Medicare Part B</b>																	
<div style="background-color: yellow; padding: 2px; font-weight: bold; font-size: small;">Select one or multiple choices</div> <p>                     Cutaquig® 16.5%      Hizentra® 20%                      Cuvitru™ 20%      prefilled syringe                      Gammagard® liquid 10%      Hizentra® 20% vial                      Gammaked™ 10%      Xembify® 20%                      Gamunex®-C 10%      Any brand                         Other                         _____                 </p>	<p>                     Infuse _____ gram(s)                      OR _____ mg per kg OR                      OR _____ grams per kg subcutaneously                        Once weekly      Every 2 weeks                      Other frequency _____                      (where clinically appropriate, round to the nearest vial size)                 </p>	<p>                     Infuse total dose of immune globulin subcutaneously in 1 to multiple sites via infusion pump as tolerated. Infusion rates per manufacturer recommendation as tolerated.                 </p>															
<p>                     HyQvia™ (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase 160 units per mL)*                      Total IG grams: _____                 </p> <p>                     Infuse total grams per the ramp up schedule, then infuse total grams:                          <b>every 4 weeks.</b>                          <b>every 3 weeks.</b>                      Where clinically appropriate, round each dose to the nearest vial size.                 </p>	<p>Ramp up schedule:</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th>Treatment interval</th> <th>4 weeks</th> <th>3 weeks</th> </tr> </thead> <tbody> <tr> <td>1st infusion</td> <td>1st week grams x 0.25</td> <td>grams x 0.33</td> </tr> <tr> <td>2nd infusion</td> <td>2nd week grams x 0.50</td> <td>grams x 0.67</td> </tr> <tr> <td>3rd infusion</td> <td>4th week grams x 0.75</td> <td>give total dose</td> </tr> <tr> <td>4th infusion</td> <td>7th week give total dose</td> <td></td> </tr> </tbody> </table>	Treatment interval	4 weeks	3 weeks	1st infusion	1st week grams x 0.25	grams x 0.33	2nd infusion	2nd week grams x 0.50	grams x 0.67	3rd infusion	4th week grams x 0.75	give total dose	4th infusion	7th week give total dose		<p>                     Infuse Hyaluronidase subcutaneously in 1–2 sites at 1–2mL per minute per site as tolerated. For each full or partial vial of immune globulin infused, administer the entire contents of the Hyaluronidase vial. Infuse total dose of immune globulin subcutaneously in 1–2 sites via infusion pump as tolerated. Infusion rates per manufacturer recommendation. Flush infusion line with 0.9% Normal Saline 10mL as needed for full dose administration.                 </p>
Treatment interval	4 weeks	3 weeks															
1st infusion	1st week grams x 0.25	grams x 0.33															
2nd infusion	2nd week grams x 0.50	grams x 0.67															
3rd infusion	4th week grams x 0.75	give total dose															
4th infusion	7th week give total dose																
<p>You have indicated which medication(s) are prescribed for this patient. You acknowledge that each medication selected is clinically appropriate for the patient. Signing this form authorizes Accredo to dispense one prescribed medication from your selection above based upon information available to Accredo, including clinical information, insurance requirements, and medication availability at the start of therapy and for the duration of this valid prescription. Accredo will communicate to you the medication dispensed to your patient. Dispensing confirmation and status updates will also be available at <a href="http://MyAccredoPatients.com">MyAccredoPatients.com</a>.</p>																	
<p><b>Premedication to be given 30 minutes prior to infusion:</b> <i>(please strike through if not required)</i></p> <ul style="list-style-type: none"> <li>• Diphenhydramine 25mg by mouth for mild infusion reactions, may increase to 50mg for history of moderate to severe (contraindicated in patients with myasthenia gravis)</li> <li>• Acetaminophen 650mg by mouth</li> <li>Other _____</li> </ul>																	
<p>For patients weighing less than 60kg, the following weight-based dosing range will be used: Acetaminophen: 10–15mg/kg</p> <p>For pediatric patients, the following weight- and age-based dosing range will be used:</p> <p>≤9kg and/or &lt;2 years old: Diphenhydramine 1mg/kg up to max of 6.25mg</p> <p>2–5 years old and &gt;9kg: Diphenhydramine 6.25mg to 12.5mg</p> <p>6–12 years old: Diphenhydramine 12.5 to 25mg</p>																	
<p><b>Medications to be used as needed:</b> <i>(please strike through if not required)</i></p> <ul style="list-style-type: none"> <li>• Diphenhydramine 25mg by mouth every 4–6 hours as needed for mild infusion reactions, may increase to 50mg for moderate to severe; maximum of 4 doses per day (contraindicated in patients with myasthenia gravis)</li> <li>• Lidocaine 4% applied topically to insertion site prior to needle insertion as needed to prevent site pain</li> <li>• Acetaminophen 650mg by mouth every 4–6 hours as needed for fever, headache or chills; maximum of 4 doses per day</li> </ul>																	

Patient's first name \_\_\_\_\_ Last name \_\_\_\_\_ Middle initial \_\_\_\_\_ Date of birth \_\_\_\_\_

Prescriber's first name \_\_\_\_\_ Last name \_\_\_\_\_ Phone \_\_\_\_\_

## 4 Prescribing Information

**Adverse reaction medications:** *(Accredo will provide an epinephrine auto injector with the first fill only)*

- Epinephrine 0.3mg auto-injector 2-pk for patients weighing greater than or equal to 30kg. Administer intramuscularly as needed for severe anaphylactic reaction times one dose
- Epinephrine 0.15mg auto-injector 2-pk for patients weighing less than 30kg. Administer intramuscularly as needed for severe anaphylactic reaction times one dose
- Diphenhydramine 25mg by mouth for mild allergic reactions and 50mg for moderate to severe

**Supplies:** *(please strike through if not required)*

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.

**Quantity/Refills:** Dispense 1-month supply. Refill x 1 year unless noted otherwise.      Dispense 90-day supply. Refill x 1 year unless noted otherwise.

Other \_\_\_\_\_

**Accredo nursing services:** *(please strike through if not required)*

Skilled nursing visits to educate patient on subcutaneous access, medication administration, use of supplies, therapy and disease state and to assess general status and response to therapy; patient discharged from nursing once teaching complete.

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

**Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)**

**SIGN  
HERE**

\_\_\_\_\_ **Date**

\_\_\_\_\_ **Dispense as written**

\_\_\_\_\_ **Date**

\_\_\_\_\_ **Substitution allowed**

Pharmacist selection allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.